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The molecular coupling of CAS and Crk in response to integrin activation is an evolutionary conserved signaling module that controls cell
proliferation, survival and migration. However, when deregulated, CAS/Crk signaling also contributes to cancer progression and
developmental defects in humans. Here we highlight recent advances in our understanding of how CAS/Crk complexes assemble in cells to
modulate the actin cytoskeleton, and the molecular mechanisms that regulate this process. We discuss in detail the spatiotemporal dynamics
of CAS/Crk assembly and how this scaffold recruits specific effector proteins that couple integrin signaling networks to the migration
machinery of cells. We also highlight the importance of CAS/Crk signaling in the dual regulation of cell migration and survival mechanisms
that operate in invasive cells during development and pathological conditions associated with cancer metastasis.
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Integrins are a large family of transmembrane receptors
that not only facilitate cell adhesion to proteins in the
extracellular space, but also transmit signals to control
numerous biological processes including cell proliferation,
survival and migration [1,2]. Of the numerous signals
emanating from integrin receptors, tyrosine phosphorylation
of the docking protein p130CAS (Crk-associated substrate,
CAS) and its recruitment and binding of the adaptor protein
c-CrkII (CT10 regulator of kinase, Crk) have proven to be a
critical response in controlling integrin-dependent process-
es. Indeed, research over the past years indicates that
assembly of this molecular signaling scaffold plays a critical
role in organization of the actin cytoskeleton leading to cell
migration [3,4], invasion [5,6], phagocytosis [7] and sur-
vival [5,8]. Furthermore, Crk and its effector proteins are
evolutionarily conserved and serve similarly important
functions in eukaryotic development. In C. elegans, genes
regulating cell engulfment and cell migration (ced-2, ced-5,0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: klemke@scripps.edu (R.L. Klemke).ced-10 and ced-12) encode for homologous proteins to the
mammalian c-CrkII, DOCK180, Rac1 and ELMO1, respec-
tively [9,10] (Fig. 1). However, deregulation of Crk func-
tion in adult organisms may contribute to the progression of
cancer and human disease [11]. In this review, we present
what is known about the molecular mechanisms that control
the assembly of CAS/Crk and its effectors, and we discuss
the recent advances in our understanding of how these
processes are spatiotemporally regulated to control cell
migration and survival under normal and pathological states
associated with cancer progression.2. CAS and Crk family members
The Crk family adaptors (c-CrkI, c-CrkII, c-CrkIII, CrkL,
v-Crk) are comprised of Src Homology 2 (SH2) and Src
Homology 3 (SH3) domains (Fig. 2A) that serve to assem-
ble macromolecular protein complexes and target them to
distinct regions within the cell [12–14]. Surprisingly, de-
spite the lack of any kinase domain, the retroviral-encoded
oncogene v-Crk can initiate transformation of chicken
fibroblasts and induce tumors in animals [15]. Since the
presence of CrkSH2 and CrkSH3 domains alone can trigger
Fig. 1. Conserved Crk-signaling pathways in mammalian cells and C.
elegans.
D. Chodniewicz, R.L. Klemke / Biochimica et Biophysica Acta 1692 (2004) 63–7664oncogenic transformation as well as normal cellular
responses, it has been the focus of many studies to identify
the effector proteins that selectively bind to these domains
and to understand how they transmit intracellular signals to
specifically control various biological processes (for recent
reviews, see Refs. [16–18]).
The c-crk gene encodes three alternatively spliced trans-
lation products: c-CrkI, c-CrkII (hereafter referred to as
Crk), and the recently identified c-CrkIII [19]. While the
mammalian Crk family members share similar overall
structure, the biological differences between each member
is not entirely clear. c-CrkII is a 42-kDa protein consisting
of one SH2 and two SH3 domains, CrkSH3(1) and
CrkSH3(2). The SH3 domains are separated by a spacer
region that contains a critical negative regulatory tyrosine at
residue 221 (Y221). Upon phosphorylation of this residue,
Crk undergoes an intramolecular folding response in which
its own SH2 domain interacts with Y221 [20,21]. This
prevents binding of Crk to tyrosine-phosphorylated proteins
including CAS, and inhibits the binding of effectors to its
SH3(1) domain. c-CrkI was found to have 60% sequence
homology to c-CrkII and differ in sequence primarily with
the absence of the second SH3 domain [22]. Also, c-CrkI
does not contain the Y221 negative regulatory site and
immunoprecipitates with increased levels of tyrosine-phos-
phorylated proteins, when compared to c-CrkII [6]. Further-
more, while CrkL contains a similar tyrosine residue to
Y221 at position 207 (Y207), there is no evidence availableFig. 2. Domain structures of the Crk (Ato suggest that this site regulates intramolecular folding
similar to c-CrkII. The preferred binding motif for CrkSH2
domains predominantly contains a phosphorylated tyrosine
residue followed by a proline in position + 3 [23]. The
specific binding proteins which contain multiple pTyr-x-x-
Pro sequences and associate with the SH2 domain of Crk
include paxillin [24–27], CAS [25,28–30], c-Cbl [31–34],
STAT5 [35,36], Gab2 [37,38], PI3K [39,40] and SHIP [41–
43] (Fig. 3). Alternatively, the selective CrkSH3(1) domain
typically binds to proline-rich motifs with the consensus
sequence of Pro-x-x-Pro-x-Lys [44], and recognizes proteins
including C3G [45–48], DOCK180 [49,50], c-Abl [51–55],
Sos [56], Eps15 [57–59] and JNK [60,61] (Fig. 3). On the
other hand, the CrkSH3(2) domain shows a limited ability to
interact with effector proteins, and to date has been dem-
onstrated to only bind the nuclear export factor Crm1/
exportin [62]. The cloning and identification of c-CrkIII,
which differs mainly from c-CrkII in its truncated C-
terminal SH3 domain, may provide future insight into the
unknown function of this particular domain [19]. Interest-
ingly, in c-CrkIII the Crm1 binding site lies just outside the
conserved CrkII sequence, and as a result, CrkIII lacks the
ability to bind this nuclear export factor. This could explain
observations by Prosser et al. indicating that CrkIII localizes
to the nucleus of human mesangial cells, and certainly begs
the query of the biological function of nuclear-localized c-
CrkIII [19]. Recent evidence also indicates that the
CrkSH3(2) domain is necessary for Crk-mediated cell
transformation, which suggests that additional effectors
interact with this region of Crk [19]. CrkL, which has an
overall similar structure to c-CrkII, is also composed of one
SH2 and two SH3 domains and sequence comparison shows
high homology to c-CrkII [63]. CrkL has been reported to
be tyrosine-phosphorylated in patients with chronic myeloid
leukemia (CML) and involved in integrin-mediated cell
migration [22,64,65]. The CrkL SH2 domain appears to
have the same specificity for pTyr-x-x-Pro motifs and
associates with similar sets of proteins as c-CrkII in vitro,
suggesting that in many cases these proteins share similar
functions [22]. In this review, we focus primarily on the) and CAS (B) family members.
Fig. 3. CAS/Crk and their binding partners. Refer to the legend in Fig. 2 for domain abbreviations. A partial list of references that address the protein/Cas/Crk
interaction is given. The following references are refered to only in this figure [107,108,111–116].
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proteins control specific signaling events.
The CAS family now includes at least three distinct
proteins in mammals and invertebrates that include the
homologous Human enhancer of filamentation/Cas-Like
(Hef1/CASL) and Embryonal fyn-associated substrate/Src-
interacting protein (Efs/Sin) [66–68] (Fig. 2B). The cloning
of CAS cDNAs revealed a protein consisting of an amino-
terminal SH3 domain, a substrate domain consisting of
multiple SH2-domain binding motifs (Tyr-x-x-Pro), proline
and serine-rich regions, and several tyrosine residues near
the C-terminus [30,68,69]. The various domains within
CAS enable it to interact with numerous cellular proteins
(Fig. 3), and CAS appears to function as a multi-site
docking protein to recruit required binding partners follow-
ing activation of specific signaling pathways. However, the
regulation and function of many CAS/multi-protein com-
plexes is still unclear. The Hef1/CASL and Efs/Sin family
members share similar domain structure and sequence
similarities with CAS (Fig. 2B), with the most notable
difference being in the absence of the proline-rich region
in Hef1/CASL. While CAS family members contain struc-
tural similarity, they appear to have distinct differences in
tissue expression and subcellular localization. The expres-
sion of CAS is observed in most adult tissues, while Hef1
mRNA expression is lower in the brain and liver and is
observed primarily in lymphocytes [70,71], and the expres-sion levels of Efs/Sin are greatest in embryonic tissues [67].
Within the cell, all three family members are largely
cytoplasmic, but CAS and Hef1 have been shown to
translocate to focal adhesion complexes following integrin
activation [70,72,73].3. Integrin-mediated mechanisms of CAS/Crk coupling
The substrate domains of CAS proteins have been
reported to be heavily tyrosine-phosphorylated upon integ-
rin activation events [74,75], and the assembly of CAS with
the SH2(1) domain of Crk is critically dependent on its
phosphorylation state. Increased tyrosine phosphorylation of
the CAS substrate domain is necessary for proper cell
spreading and migration on various ECM proteins [76,77].
However, the precise mechanism by which CAS is tyrosine-
phosphorylated by integrins is unclear due to the ability of
CAS to interact with both the Src and focal adhesion kinase
(FAK) families via its C-terminal and SH3 domains, respec-
tively. The SH3 domain of CAS may regulate the phos-
phorylation of its substrate domain and subsequent
downstream signaling events through recruitment of FAK
[25,78,79], as well as the proline-rich tyrosine kinase-2,
Pyk2 [80,81], and the tyrosine phosphatases, PTP-PEST
[82] and PTP-1B [83]. Additionally, the tyrosine residues at
the C-terminus provide binding sites for the SH2 and SH3
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[84] and several other proteins [28,85]. Of the vast number
of proteins which can assemble with CAS and Crk (Fig. 3),
many have typically been associated with organization of
the actin cytoskeleton and the migration machinery of the
cell [3,74].
While FAK and Src are good candidates as regulators of
CAS phosphorylation, a major question remains as to what
kinases phosphorylate CAS to promote CAS/Crk coupling.
Coordinate phosphorylation of CAS and FAK has been
observed during cell adhesion [74,75,86] and these proteins
are colocalized in focal adhesion contacts [73]. FAK-pro-
moted tyrosine phosphorylation of CAS has also been
linked to cell migration [76,77]. However, in FAK-null
cells, some studies have reported no change in levels of
phosphorylated CAS when compared to cells reexpressing
FAK [87], and CAS is a poor substrate of FAK in vitro [88].
The FAK-related kinase, Pyk2, has been reported to be up-
regulated in FAK-null cells and may compensate in lieu of
FAK [81,87]. Despite its apparent kinase function though,
FAK has also been implicated to serve as a docking protein
in recruiting and activating Src family kinases, which lead to
CAS phosphorylation [88]. Src kinases have also been
demonstrated to directly promote tyrosine phosphorylation
of the substrate domain of CAS, as phosphorylated CAS in
Src-null cells is significantly lower than control cells recon-
stituted with Src [73,89–92]. Additionally, the phosphory-
lation of CAS on tyrosine 253 by Src has recently been
demonstrated to be required for Src to augment cell migra-
tion, but not required for Src to enhance the effects of CAS
on growth rate and anchorage independence [93]. Thus, it is
likely that FAK and Src synergistically work together to
phosphorylate the substrate domain of CAS in response to
integrin ligation. However, it appears that future work is
necessary to precisely determine how these tyrosine kinases
function to regulate CAS/Crk assembly downstream of
integrin activation.
Once tyrosine-phosphorylated, CAS manifests its down-
stream signaling primarily through its association with Crk
and its associated effectors, and many studies have reported
integrin-mediated CAS/Crk assembly [3,76,91,94–97].
CAS/Crk complexes signal reactions that eventually result
in the activation of Rac1 via a functional cooperation
between the GTPase-activating protein DOCK180 and
ELMO1, which serve to target Rac1 activation to discrete
intracellular locations [49,98,99]. In addition to integrin-
mediated CAS/Crk signaling, many growth factors have
been reported to induce rearrangements of the actin cyto-
skeleton concomitant with increased levels of CAS tyrosine
phosphorylation and subsequent CAS/Crk coupling
[5,39,45,76]. Upon stimulation with epidermal growth fac-
tor (EGF), platelet-derived growth factor (PDGF) or insulin,
cells exhibit rapid cytoskeleton rearrangement initiated
through a phosphatidylinositol 3V-kinase (PI3K)-dependent
activation of Rac1 [100–102]. Furthermore, following EGF
and PDGF stimulation, CAS phosphorylation was observedto exhibit a bell-shaped dose–response curve, which re-
quired PI3K catalytic activity [103,104], and low concen-
trations of EGF stimulated the formation of CAS/Crk
complexes [103]. These data suggest that CAS/Crk could
participate in growth factor signaling, possibly involving
cross-talk between integrin-mediated activation events in-
volving FAK and Src family kinases. Other growth factors/
chemokines have also been reported to promote CAS
phosphorylation, suggesting that numerous growth and
motility signals may operate through CAS/Crk coupling
and its upstream regulators [39,45].
In contrast to the positive regulation of CAS/Crk assem-
bly discussed above, several effector proteins have been
reported to negatively regulate CAS/Crk coupling. For
example, c-Abl phosphorylates Crk at tyrosine Y221 result-
ing in the decoupling of CAS/Crk complexes and the
interruption of cell migration [5,8]. On the other hand,
dephosphorylation of Crk-Y221 by PTP-1B promotes in-
creased CAS/Crk coupling and cell migration [4]. Also,
cells expressing activated PTP-PEST exhibited defective
migration that was paralleled with a decrease in levels of
tyrosine-phosphorylated CAS [94,105]. In addition to an
uncoupling of CAS/Crk complexes, reports have indicated
cleavage of CAS by caspase-3 to coincide with a delocal-
ization of FAK from sites of focal contacts [106]. The
decoupling of CAS/Crk complexes and the cleavage of
CAS are observed events during apoptosis, and accordingly,
disruptions in CAS/Crk signaling appear to prevent the
transmission of survival signals from the cytoskeleton (dis-
cussed below).
Taken together, the phosphorylation states of CAS and
Crk appear to be critical in selectively activating distinct
signaling pathways that determine the fate of a cell, such as
migration or apoptosis. The future challenge will be to sort
out which posttranslational modifications are necessary for
CAS/Crk signaling, and when, where and how these mod-
ifications coordinately cooperate with other effectors to
dynamically regulate the processes involved in cell function.4. Spatiotemporal regulation of CAS/Crk assembly/
disassembly
While the spatial and temporal assembly of CAS and Crk
is not understood, recent evidence has shed some insight
into this process. In suspended cells, Crk is primarily limited
to the cytoplasm, whereas upon cell attachment and integrin
activation, Crk becomes tyrosine-phosphorylated at residue
Y221 and translocates to the plasma membrane. The ex-
pression of a Crk tyrosine 221 to phenylalanine mutation
(CrkII-Y221F) caused Crk to be retained in the cytoplasm,
preventing its localization to the membrane [117], and
interestingly, Rac also failed to translocate to the membrane
and induce membrane ruffles and cell migration. Even the
coexpression of constitutively active Rac (RacV12) failed to
localize to the membrane in these cells [117]. However, this
Fig. 4. Model of Abl-mediated Crk translocation to the membrane/focal
adhesions. Initially, Crk is present in the cytosol (1). Upon c-Abl
phosphorylation of Crk at Y221 (2), Crk undergoes an intramolecular
rearrangement in which its SH2 domain folds back and binds Y221.
Additionally, the PPP motif within the CrkSH2 domain further interacts with
the SH3 domain of Abl (3). The folded-Crk protein is rapidly translocated to
the membrane and/or focal adhesions by Abl, where a phosphatase like PTP-
1B dephosphorylates Y221 enabling Crk to unfold (4). Crk can then interact
with CAS and DOCK180, as well as other effector proteins, leading to Rac
activation, pseudopod extension and cell migration (5).
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overcome by targeting RacV12 or CrkII-Y221F to the
membrane with a myristylation sequence, suggesting that
Crk mediates Rac translocation to the membrane.
A genetically encoded fluorescent resonance energy
transfer (FRET) indicator that directly reports Crk-Y221
phosphorylation in living cells showed strong Crk-Y221
phosphorylation in membrane ruffles [118]. In this report,
PDGF stimulation of cells revealed a pattern of Crk phos-
phorylation that began in the cytoplasm surrounding the
perinuclear region of the cell body and emanated outward to
membrane ruffles in the extending lamellipodium. Similarly,
early work using immunofluorescence and phosphospecific
antibodies to the Crk-Y221 site also revealed a significant
level of phosphorylated Crk in membrane ruffles [119].
Interestingly, in CrkII-Y221F mutated cells, the FRET
reporter did not localize to membrane ruffles and no FRET
activity was observed in the membrane (R.L. Klemke and
K.H. Kain, unpublished data). Based on these studies, it
appears that Crk phosphorylation first occurs in the cyto-
plasm and then rapidly moves to peripheral membrane
ruffles in stimulated cells. Although the mechanism of
translocation is not known, apparently it does not require
functional SH2 and SH3 domains as phosphorylated Crk
would be expected to be in an inactive folded conformation
unavailable to associate with its binding partners. Alterna-
tively, the SH2 domain of Crk contains a polyproline
sequence (PPPP) that is exposed upon binding to phospho-
tyrosine residues including its own Y221 [21]. This raises
an intriguing possibility that the PPPP motif of Crk binds to
the SH3 domain of a shuttle protein that transports phospho-
Crk to the membrane. As discussed below, Abl tyrosine
kinase is a possible candidate as it phosphorylates Crk-Y221
and can interact with the PPPP region through its SH3
domain [21]. In any case, the tyrosine phosphorylation of
Crk at Y221 is a critical event for intracellular translocation
of Crk and Rac from the cytoplasm to the membrane in
response to integrin and/or growth factor receptor ligation.
Upon translocation to the membrane, how does Crk
associate with CAS and regulate Rac activity? In the
simplest case, Crk phosphorylation induces translocation
to membrane ruffles, where it is rapidly deposphorylated by
a phosphatase like protein tyrosine phosphatase-1B (PTP-
1B) [4] (Fig. 4), and dephosphorylated Crk is then available
to couple to its downstream effector proteins. Tyrosine-
phosphorylated CAS has been shown to localize to the
extending lamellipodia of migrating cells and CAS/Crk
complexes are highly enriched in purified lamellipodia
structures [76,92,120]. The localized CAS/Crk complexes
then recruit DOCK180 and Rac leading to GTPase activa-
tion, actin dynamics and cell migration (Fig. 4). However,
this may not always be the case, as more recent evidence
indicates that integrin activation promotes dephosphoryla-
tion of Crk-Y221 through activation of PTP-1B, resulting in
increased CAS/Crk complexes and motility [4]. It was also
shown in this study that expression of Crk-Y221F in cellsincreased CAS/Crk coupling and migration. The discrepan-
cy in these reports may be due to different cell types and
expression levels of Crk-Y221F utilized by these groups.
However, in either case, these studies illustrate the impor-
tance of Crk-Y221 phosphorylation in the regulation of cell
migration and point to the need for additional studies to
clarify the role of integrins in modulating this process in
time and space.
While CAS/Crk/Rac localize to membrane ruffles and
these proteins are necessary for cell migration, there is also
compelling evidence that this signaling module localizes to
focal adhesions. Using antibodies directed against phos-
phorylated YxxP tyrosines of the CAS substrate domain,
tyrosine-phosphorylated CAS has been shown to localize to
newly forming focal adhesions in extending lamellipodia as
D. Chodniewicz, R.L. Klemke / Biochimica et Biophysica Acta 1692 (2004) 63–7668well as mature focal adhesions underlying the cell body of
migrating cells [92]. Additionally, CAS has been shown to
function in recruiting Crk to focal adhesions [91,121], and
Crk, in turn, recruits DOCK180 to these structures [98]. The
assembly of a CAS/Crk/DOCK180 scaffold at focal adhe-
sions could drive localized Rac activity leading to actin
polymerization and recruitment of high-affinity integrin
receptors necessary for lamellipodium extension and cell
migration [122]. In support of this, forced targeting of CrkL
to focal adhesions has been shown to be sufficient to recruit
DOCK180 to these structures and to induce Rac and Cdc42
activity leading to cell migration [64]. It is important to note
that the initial protrusion of a lamellipodial membrane away
from the cell body does not require integrin-dependent
signaling events, as cells display random membrane protru-
sion as well as directional extension towards chemokine
gradients independent of the ECM [123,124]. This places
the initial Rac activation upstream of ECM-driven integrin
signaling processes. However, as a lamellipodium extends,
it must attach to the ECM, otherwise it rapidly retracts back
to the cell body [124–126]. Therefore, integrin ligation
events at the front of the lamellipodium provide positive
feedback signals to maintain Rac activity, which leads to a
persistent and directional membrane protrusion. Loss of
ECM substrate contacts would turn off the positive feedback
signal provided by Rac, preventing further lamellipodial
extension. In this manner, integrins serve to regulate lamel-
lipodial dynamics and fine-tune directionality during cell
migration. Indeed, biochemical purification of lamellipodia
in either the growth or retraction phase revealed the dynamic
coupling/uncoupling of CAS/Crk complexes and Rac acti-
vation, respectively [120]. In this study, forced CAS/Crk
coupling was found to maintain lamellipodia extension and
prevent membrane deadhesion and retraction from the
substratum. Furthermore, persistent Rac activation in cells
promoted sustained CAS/Crk coupling and prevented lamel-
lipodium retraction, supporting the notion that this signaling
pathway serves as a positive feedback mechanism for
controlling membrane dynamics [120]. Thus, during cell
migration, integrin-mediated attachment of the lamellipo-
dium to the supporting ECM is critical not only for the
generation of traction force (Ref. [127] and references
therein), but also for signal transduction processes that
stabilize and fine-tune the direction of the extending mem-
brane as it navigates the ECM. On the other hand, Rho
activation appears to play a necessary role in lamellipodium
retraction [123].
A key question remains as to how the CAS/Crk/
DOCK180 scaffold assembles/disassembles within the spe-
cialized lamellipodial compartment. Surprisingly, biochem-
ical examination of lamellipodia under growth and
retraction conditions revealed that Crk uncouples from
CAS without apparent changes in FAK activity and CAS
tyrosine phosphorylation [5,123]. In this case, uncoupling
may occur via dephosphorylation of only a subset of the
specific Try-x-x-P motifs, which interact with the SH2domain of Crk, and not through global dephosphorylation
of CAS. It will be necessary to map the specific tyrosine
sites in the CAS substrate domain and determine which
one(s) are regulated in migrating cells. Furthermore, al-
though Crk phosphorylation at Y221 has been shown to
prevent CAS/Crk coupling, it is unlikely that this is the
primary mechanism used by the lamellipodium to uncouple
this scaffold, as the pool of phosphorylated Crk-Y221
remains relatively unchanged in growing and retracting
lamellipodia (R.L. Klemke and D. Chodniewicz, unpub-
lished data). Therefore, it seems more likely that a tyrosine
phosphatase, such as PTP-PEST or PTP-1B, targets dephos-
phorylation of specific Crk-binding motifs within the CAS
substrate domain [94,105]. While progress has been made in
understanding the biochemistry of CAS/Crk coupling, iden-
tification of the precise location and time that this process
occurs within the cell will require development of novel
FRET reporters and phosphospecific antibodies against
regulatory residues on CAS [92] and Crk. Such high-
resolution tools will undoubtedly uncover novel spatiotem-
poral information about the organization of this signaling
module within dynamic, motile cells.5. Abl family kinases are key regulators of CAS/Crk
assembly
The Abl family includes c-Abl and the c-Abl-related
gene, arg (for recent review, see Ref. [128]). These enzymes
are highly homologous, being comprised of SH2, SH3, actin
binding, polyproline and tyrosine kinase domains [129].
While their similar domain structure strongly suggests that
they may function redundantly [54,128], there are notable
differences including the ability of c-Abl to shuttle between
the nucleus and cytoplasm, due to its nuclear localization
sequences which are absent from the arg gene product
[130]. Furthermore, approximately 75% of abl / ani-
mals die postpartum, and although viable, the surviving
mice exhibit behavioral defects including thymic atrophy,
lymphopenia, osteoporosis, improper eye development and
spermatogenesis [131]. When both the abl and arg genes are
deleted, animals die early in development (E9–11) from
neurological defects [132].
The molecular mechanism by which Abl and Arg are
spatially and temporally regulated is multi-faceted, as these
enzymes are dynamically controlled by diverse extracellular
factors including integrins, growth factors and apoptotic
agents [131,133]. Interestingly, upon integrin ligation or
cytokine exposure, Abl/Arg are reported to be activated and
localize to areas of CAS/Crk assembly including focal
adhesions and membrane ruffles [55,110,134,135]. This
and the fact that both Abl and Arg interact with the SH3
domain of Crk via their conserved polyproline region, and
promote tyrosine phosphorylation of Crk-Y221 [8,109,136],
set the stage for recent work demonstrating an important
biological role for Abl family kinases in the regulation of
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apoptosis (discussed below). These studies demonstrated
that a kinase dead form of Abl or exposure of cells to the
Abl kinase inhibitor STI 571 enhanced CAS/Crk coupling
and cell migration by decreasing phosphorylation of Crk-
Y221 [137]. Conversely, expression of a constitutively
activated form of Abl prevented the assembly of CAS/Crk
complexes and inhibited cell migration, which was depen-
dent upon a functional PPPP domain and Crk-Y221 phos-
phorylation [8,136,137]. Examination of this signaling
pathway in embryonic fibroblast cells isolated from
abl / arg / deficient mice [132] revealed a com-
plete loss of basal Crk-Y221 phosphorylation. These cells
also exhibited increased CAS/Crk coupling and cell migra-
tion, and reconstitution of these cells with Abl reversed this
response. A similar Abl-dependent pathway may also exist
to regulate HGF-induced motility, as cells exposed to STI
571 showed enhanced cell migration in response to this
growth factor [138], and Crk is known to play an important
role in mediating HGF-induced cell migration [139]. How-
ever, in the case of PDGF signaling, Abl activity may play a
positive role by increasing chemotactic motility via down-
regulation of phospholipase C-g1 (PLC-g1) activity. How
this signaling process couples to the migration machinery is
not known, but must be different from previous work that
demonstrated a positive role for PLC-g1 activity in cell
motility [140,141].
A central question remains as to how integrins regulate
Abl/Arg activity to negatively modulate CAS/Crk coupling
and cell migration, especially in light of the fact that integrin
ligation is known to promote activation and translocation of
Abl from the nucleus to focal adhesions [135]. One possi-
bility is that integrin-mediated Abl activation serves as a
negative feedback pathway to control the level of CAS/Crk
coupling through direct phosphorylation of Crk-Y221. This
would effectively reduce the pool of active Crk available to
interact with phosphorylated CAS following integrin activa-
tion. Such a negative feedback signal would be expected to
operate transiently downstream of integrins to bring about
steady state levels of CAS/Crk complexes in cells, as is the
case with Abl [8,135,137,142]. Also, the increased associa-
tion of Abl with the SH3 domain of Crk may displace
positive effectors like DOCK180 that facilitate cell migra-
tion, which would reinforce the negative inhibition of cell
migration by Abl. Interestingly, Abl phosphorylation and the
molecular folding of Crk has been shown to unmask a PPPP
motif in Crk that can further interact with the SH3 domain of
Abl, providing increased molecular stability to this protein
complex. The Abl/Crk complexes would then be in position
to outcompete positive effectors for binding to the SH3
domain of Crk [17,21]. Also, mutations in the CrkSH3(2)
domain and linker region have been shown to increase Abl
binding to the CrkSH3(1) domain, suggesting an additional
mechanism for regulation of Abl/Crk formation [143].
The dynamic nature of Abl, along with its ability to both
phosphorylate and tightly bind Crk, suggests that this en-zyme could also serve as a shuttle protein to deliver phos-
phorylated Crk to the membrane and/or focal adhesions
[3,144] (Fig. 4). In this case, integrin-induced signals would
induce formation of Abl/Crk complexes and their transloca-
tion to the membrane and/or sites of focal adhesions. Abl
would then retain inactive Crk in these structures until
dephosphorylation of Crk-Y221 occurs by a tyrosine phos-
phatase resulting in the disassociation of Abl, leaving Crk
free to interact with other proteins like CAS and DOCK180
(Fig. 4). Under these conditions, integrin-mediated activa-
tion of Abl would provide a sensitive mechanism to modu-
late the pool of active/inactive Crk available to bind effectors
in distinct compartments of the cell. However, while this
model is supported by evidence that Crk-Y221 phosphory-
lation is necessary for Crk translocation, Rac activation and
motility [117], it does not explain why cells migrate better in
the complete absence of Abl and Arg proteins or when Abl
kinase activity is blocked with STI 571 [8,137,138]. This
seems conflicting with the speculative function of Abl as a
transporter of Y221-phosphorylated Crk to the membrane, as
well as the requirement for Crk-Y221 phosphorylation in
Rac-dependent signaling events and motility [3,145]. It is
possible that abl / arg / cells utilize a different
tyrosine kinase to phosphorylate and target Crk to critical
regions in the cell, or utilize a Crk-independent mechanism
altogether to regulate Rac translocation and activation. Abl
has been shown to regulate actin-mediated microspike for-
mation independent of the Rho-family GTPases [146].
However, abl / arg / cells exhibit an impaired
Crk-Y221 phosphorylation in response to several stimuli
including integrin activation, PDGF and apoptotic agents
like H2O2 (Ref. [137]; R.L. Klemke and K.H. Kain unpub-
lished data). Also, under steady-state conditions the small
pool (10–20%) of Y221-phosphorylated Crk seen in most
adherent cells is completely absent in abl / arg /
cells, but returns when Abl is placed back into these cells
[8,137]. This strongly implicates endogenous Abl/Arg
kinases as the primary regulators of Crk phosphorylation,
and points to an important housekeeping role for maintaining
appropriate levels of phosphorylated Crk in cells. Future key
studies will be to examine whether Crk retains the ability to
translocate to the membrane and/or focal contacts in abl /
 arg / cells, and the mechanism of integrin-mediated
Rac activation in cells without functional Abl family kinases.
Also, it will be important to identify the upstream compo-
nents responsible for integrin activation of Abl family
kinases. In this case, Src would be a good candidate as it is
activated by integrins and can in turn activate Abl and
regulate cell migration [8,110,147].6. Coordinate regulation of cell survival and migration
by CAS/Crk scaffolds
Migratory cells must coordinately activate survival
mechanisms to invade the ECM and to colonize foreign
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lance, wound healing and angiogenesis. Inappropriate
regulation of these processes contributes to unwanted
survival of metastatic cancer cells, autoimmune disease
and developmental abnormalities. Micrometastases are a
particular problem because these cells have turned on
migratory pathways that allow them to leave the primary
tumor and travel to foreign sites, where they can lie
dormant for several years avoiding apoptotic programs
[148,149]. Current evidence indicates that adhesive pro-
teins present in the ECM not only provide migratory
substrates, but also coordinately induce survival signals
that allow these cells to invade and colonize new areas in
the body. On the other hand, migratory cells that fail to
recognize or remodel the ECM, or stray from the proper
ECM path, are eliminated through activation of apoptotic
mechanisms, as is the case with neural crest cell migration
[150].
Recently, integrin-mediated signals involving Abl fam-
ily kinases and CAS/Crk coupling have emerged as po-
tential regulators of both motility and apoptotic programs
in normal and transformed cells [62,137,151]. Increased
assembly of CAS/Crk complexes in cells has been shown
to induce cell invasion in a collagen-rich matrix, and also
protect these cells from apoptosis [5]. Furthermore, human
pancreatic carcinoma cells selected for increased metastasis
in animals showed decreased Crk-Y221 phosphorylation,
increased CAS/Crk coupling, and increased survival in
response to a collagen matrix, when compared to their
noninvasive counterpart [5,137]. Not surprisingly then, it
was found that inactivation of Abl kinase facilitated
increased CAS/Crk coupling and promoted increased mi-
gration and protection from apoptosis. In contrast, disas-
sembly of CAS/Crk complexes in cells through Abl
activation or expression of mutant forms of these proteins
that disrupt CAS/Crk coupling caused cells to stop migrat-
ing and commit suicide [137]. Although the mechanism is
not known, both the migration and survival responses
required Rac activity, suggesting a close connection to
the actin cytoskeleton and focal adhesion formation
[5,137]. It is likely that uncoupling of Crk from CAS
disrupts normal survival signals that emanate from focal
adhesions and the cytoskeleton. Interestingly, withdrawal
of growth factors from cells disrupts FAK signaling which
leads to apoptosis, and this response involves signaling
through CAS [152]. Additionally, several reports have
shown Abl-mediated apoptosis following exposure of cells
to DNA-damaging agents and oxidative stress
[137,153,154], and these apoptotic agents also strongly
promote Crk-Y221 phosphorylation and disruption of
CAS/Crk signaling in cells, suggesting a role for the
Abl/Cas/Crk pathway in this death response (Ref. [137];
R.L. Klemke and D. Chodniewicz unpublished data).
Furthermore, FAK, CAS and c-Abl are cleaved by cas-
pases in apoptotic cells, providing direct evidence for
cross-talk between these cytoskeletal-associated signalsand the apoptotic machinery of the cell. Although previous
work showed that Abl regulation of Crk in apoptotic cells
occurs exclusively in the cytoplasm and not in the nucleus
[137], there is accumulating evidence that Crk can localize
to the nucleus, where it promotes apoptosis through the
Cdc2/cyclin B inhibitor, Wee1 [62]. Interestingly, Crk has
been found to contain a nuclear exclusion sequence (NES)
and to bind the nuclear export factor Crm1/exportin via its
SH3(2) domain, and expression of a mutant Crk protein
deficient in Crm1 binding promotes apoptosis of HEK 293
cells [62].
While it is becoming clear that integrin-mediated sig-
nals control both processes, it is not yet understood how
motility signals control the cell’s decision to survive or
commit suicide. Where and when these signals are acti-
vated within the cell is likely to play an important role in
this decision making process. For example, the duration of
Abl activation appears to serve a ‘rheostat-like’ function
that carefully balances the level of CAS/Crk coupling,
which then instructs the cell to either migrate or enter
apoptosis. Thus, in spreading and migratory cells where
integrin adhesions are being turned over, Abl activation is
transient, whereas in apoptotic cells, Abl activity is gen-
erally elevated and sustained for extended periods of time
[137,142,153]. The controlled, transient Abl activity is
likely to be important for fine-tuning the dynamics of
integrin adhesion and cytoskeletal rearrangement during
cell migration. Conversely, sustained Abl activity causes a
persistent uncoupling of CAS/Crk complexes and the
cessation of survival signals that emanate from the cyto-
skeleton [8,137]. This and the fact that Abl can disrupt
nuclear and mitochondrial function to induce apoptosis
could serve as a sensitive and potent ‘apoptotic switch’ to
eliminate aberrant cells. If the ‘rheostat’ shifts too much to
one side, then too little Abl activity may cause aberrant
cell migration and resistance to apoptotic control, while
too much Abl activity may cause cessation of movement
and suicide.7. CAS/Crk signaling in cancer and disease
If the endogenous role of integrin-mediated Abl activa-
tion is to down-regulate CAS/Crk coupling as a mecha-
nism to suppress cell migration and survival, why then do
constitutively activated forms of oncogenic Bcr-Abl trans-
form lymphoid cells leading to CML [155]? Typically, the
initial cellular response to activation of an oncogene or
aberrant activation of an unscheduled motility response is
to commit suicide. In rare events, a few cells avoid these
normal checkpoints and become transformed leading to
tumor formation and metastasis. Also, leukemic cells that
reside in the vasculature are not subjected to normal
integrin control pathways, but rather have activated a
cascade of signaling pathways involved in differentiation,
proliferation and suppression of apoptosis. Interestingly,
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c-CrkII suggesting that Bcr-Abl may have bypassed this
normal checkpoint [156,157]. Amplification of c-CrkII in
epithelial and fibroblast cells suppresses apoptotic mecha-
nisms and may itself be transforming as recently reported
[5,158]. While originally only CrkI had been reported to
have oncogenic potential as overexpression of CrkI readily
formed tumors in nude mice [159], recently it has been
demonstrated that amplification of the Crk protein in NIH
3T3 cells can induce cellular transformation through acti-
vation of RhoA and the serum response factor (SRF)
[158]. Additionally, the levels of the CrkI oncoprotein
and phosphorylated CrkII were significantly increased in
clinically aggressive lung adenocarcinomas [11]. Thus,
there is now evidence that all Crk family members are
capable of transforming cells and are direct targets of
several oncogenes, which strongly implicates these adaptor
proteins in cancer [12,13,137,158]. Clearly, additional
work is needed to clarify how Abl and Crk/CrkL contrib-
ute to human cancer as well as where these events operate
in cancer progression.
CAS is also likely to contribute to cancer as fibroblast
cells isolated from CAS knockout animals cannot be trans-
formed by Src and show a variety of genetic alterations due
to the loss of CAS [160]. CAS has also been shown to
contribute to antiestrogen-resistant breast cancer in humans
[161], and amplification of ErbB2 facilitates increased CAS/
Crk coupling in several breast adenocarcinoma cell lines
[162]. Furthermore, human pancreatic cells that exhibit
increased metastasis in animals show increased CAS/Crk
complexes that result from decreased Crk phosphorylation
at tyrosine 221. Clearly, work is warranted to determine
whether alterations in CAS/Crk signals are prevalent in
human cancers and whether these signals contribute to a
more aggressive phenotype leading to poor patient progno-
sis. Finally, CAS/Crk coupling has been linked to other
biological processes, including integrin-mediated adenovi-
rus internalization [84], infection of epithelial cells by
Yersinia pseudotuberculosis which causes gastroenteritis
[163], and myogenesis [164].8. Conclusions and future perspectives
In this review, we focused on the CAS/Crk-signaling
module and its role as a switch that couples integrins to the
migration and survival machineries of the cell. FAK and/or
Src tyrosine kinases appear to serve as positive amplifiers of
CAS/Crk assembly through phosphorylation of multiple
tyrosine residues in the substrate domain of CAS. Signal
amplification then results from the docking of multiple Crk
molecules to CAS, which in turn leads to the recruitment of
various effectors that couple the scaffold to the actin
cytoskeleton of the cell. Although our understanding is
incomplete, current evidence indicates that the plasma
membrane and focal adhesions are important sites whereCAS/Crk assembles to modulate cell migration and survival.
The level of CAS/Crk coupling in the cell is carefully
controlled by a negative feedback mechanism that involves
Abl-mediated Crk-Y221 phosphorylation and dephosphor-
ylation by PTP-1B. Equally important in this response is
regulated dephosphorylation of the substrate domain of
CAS via PTP-PEST, which is necessary for modulation of
Crk binding, and thus, proper organization of the cytoskel-
eton and cell migration.
In summary, while adhesive proteins in the extracellular
environment serve as a supporting network for tissues,
they also provide critical spatial and temporal information
to maintain normal homeostasis in the body through
regulation of cell polarity, differentiation, proliferation
and motility. Research over the last decade has shown that
integrins play a key role in relaying information from the
extracellular environment to the interior of the cell. This
occurs through complex signaling pathways that involve
switches, timers, oscillators and sensitive rheostats. As
with other signaling receptors, the integrin field is now
faced with understanding how these complex signaling
networks are organized to produce specific biological
responses. This is no easy challenge given the fact that
many information modules appear to cross-talk with other
signaling networks to control numerous cell processes, as
is the case with cooperative control of apoptosis and
migration by CAS/Crk coupling. A complete understand-
ing of how these signaling modules control specific
responses will be gained when we understand precisely
how they are organized in time and space, followed by
application of realistic computer modeling of probable
interactions and large scale bioinformatics. Only when this
is achieved will we be able to systematically map signaling
cascades and assign with confidence a given signaling
network, with all of its regulatory components (positive
and negative switches, amplifiers, modulators, etc.), to a
specific biological outcome. Development of FRET-tech-
nology that reports specific protein/protein interactions as
well as specific changes in protein conformation due to
activation/inactivation processes promises to provide cru-
cial information on complex signaling events in time and
space. This along with ever-increasing repertoire of anti-
bodies that detect specific posttranslational protein mod-
ifications and structural conformations that reflect activity
states will undoubtedly provide a more complete under-
standing of how complex signaling networks like the CAS/
Crk scaffold are assembled and partitioned into micro-
domains within the cell.Acknowledgements
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